• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
    • 香港
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 新聞及臨床報告
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

新聞及臨床報告

  • 首頁
  • 新聞及臨床報告
  • 臨床醫學報告
首頁 > 新聞及臨床報告 > 臨床醫學報告 > Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe

Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe

  • National Cancer Institute
  • 2023-02-27
  • 0 次瀏覽

https://www.cancer.gov/news-events/cancer-currents-blog/2016/nk-immunotherapy-leukemia 


Abstract

An immunotherapy approach that uses a new method of preparing immune cells may provide a potential treatment option for some patients with acute myeloid leukemia (AML), results from an early-stage clinical trial suggest.

In the phase I trial, researchers collected the immune cells, called natural killer (NK) cells, from donors, manipulated them to be better cancer killers, and infused the cells into patients with AML who had previously exhausted all other treatment options. The approach—which uses a new method of manipulating NK cells that is different from those used in prior studies—led to partial or complete remissions in five out of the nine patients who could be evaluated. It also appeared to be safe, with patients experiencing only minor side effects.

Results from the new study, led by Todd Fehniger, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, were published September 21 in Science Translational Medicine.

The new method for manipulating NK cells “holds promise, and is just a start,” said Mattias Carlsten, M.D., Ph.D., who studies NK-cell immunotherapy at Karolinska Institutet in Sweden, but who was not involved in the study.


Source:  Modified Immunotherapy Approach Shows Promise for Leukemia. October 21, 2016, by NCI Staff. https://www.cancer.gov/news-events/cancer-currents-blog/2016/nk-immunotherapy-leukemia 

上一篇:Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma 下一篇: Targeting dendritic cells in pancreatic ductal adenocarcinoma

欄目分類

  • 新聞 11
  • 臨床醫學報告 13

熱門文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • Cancer immunotherapy via dendritic cells
    2022-05-05
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393
  • 微信:aicl_hk

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

合作機構

  • 日本新橫濱加藤醫院

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.